Omolara Fakunle, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1780625129
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 772 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 772 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amgen$766
- Insulet Corporation$723
- Abbott$653
- Amarin Pharma, Inc.$647
- plus $7K from 48 others
What the payments were for
- Food & beverage$13,23899%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,318 in reported general payments places this provider in the 75th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 186 | $317,031 |
| JardianceEmpagliflozin | 252 | $287,623 |
| MounjaroTirzepatide | 161 | $205,299 |
| TrulicityDulaglutide | 93 | $174,856 |
| JanuviaSitagliptin Phosphate | 123 | $133,627 |
| Tresiba Flextouch U-200Insulin Degludec | 71 | $101,219 |
| FarxigaDapagliflozin Propanediol | 93 | $100,502 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $88,121 |
| Tresiba Flextouch U-100Insulin Degludec | 135 | $83,928 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $58,190 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $54,142 |
| Novolog FlexpenInsulin Aspart | 179 | $49,009 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 218 | $37,524 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $36,582 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $34,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,212 | $388,879284 claims |
| Novo NordiskOzempic, Novolog | $1,908 | $326,090211 claims |
| Boehringer IngelheimJardiance, Tradjenta | $553 | $318,439290 claims |
| MerckJanuvia, Janumet Xr | $124 | $191,817165 claims |
| AstraZenecaFarxiga | $384 | $100,50293 claims |
| Johnson & JohnsonInvokana | $242 | $26,63416 claims |
| Antares Pharma, Inc.Xyosted | $162 | $20,62022 claims |
| AbbVieSynthroid | $319 | $12,348172 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $245 | $10,187760 claims |
| IBSA Pharma Inc.Tirosint | $51 | $4,50012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
- Swapna DeoLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.